SPRY vs. NUVL, MRUS, CRSP, TGTX, CYTK, ACAD, KRYS, TLX, ADMA, and AAPG
Should you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Nuvalent (NUVL), Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), Cytokinetics (CYTK), ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Telix Pharmaceuticals (TLX), ADMA Biologics (ADMA), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry.
ARS Pharmaceuticals vs. Its Competitors
ARS Pharmaceuticals (NASDAQ:SPRY) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.
ARS Pharmaceuticals has higher revenue and earnings than Nuvalent. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.
68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 33.5% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 10.2% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
ARS Pharmaceuticals has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.
In the previous week, Nuvalent had 5 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 15 mentions for Nuvalent and 10 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 1.55 beat Nuvalent's score of 1.52 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.
ARS Pharmaceuticals currently has a consensus price target of $31.00, suggesting a potential upside of 166.78%. Nuvalent has a consensus price target of $120.80, suggesting a potential upside of 57.74%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe ARS Pharmaceuticals is more favorable than Nuvalent.
Nuvalent has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -42.74%. ARS Pharmaceuticals' return on equity of -21.85% beat Nuvalent's return on equity.
Summary
ARS Pharmaceuticals beats Nuvalent on 9 of the 15 factors compared between the two stocks.
Get ARS Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ARS Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SPRY) was last updated on 9/2/2025 by MarketBeat.com Staff
